ANIP
Ani Pharmaceuticals Stock Analysis
AI Rating
- Quality8/10
- Growth↑ 5/10
- Momentum↑ 5/10
ANIP Growth
- Revenue Y/Y↑ 48.87%
- EPS Y/Y↑ 410.91%
- FCF Y/Y↑ 72.48%
ANIP Profitability
- Gross margin ↑ 61.10%
- EPS margin↓ 4.70%
- ROIC↓ 7.60%
ANIP Risk
- Debt / Equity↓ 1.2
- Debt / FCF↓ 2.3
- Interest coverage↓ 3.3
Ani Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Good risk rating.